Investment analysts at Craig Hallum initiated coverage on shares of Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) in a research report issued to clients and investors on Tuesday,Briefing.com Automated Import reports. The firm set a "buy" rating and a $21.00 price target on the stock. Craig Hallum's price target would suggest a potential upside of 150.90% from the company's previous close.
Separately, HC Wainwright assumed coverage on Actuate Therapeutics in a research report on Monday, March 17th. They set a "buy" rating and a $20.00 price target on the stock.
Get Our Latest Stock Analysis on Actuate Therapeutics
Actuate Therapeutics Stock Up 4.6 %
NASDAQ:ACTU opened at $8.37 on Tuesday. The stock's 50 day moving average price is $7.37 and its two-hundred day moving average price is $8.05. Actuate Therapeutics has a twelve month low of $5.51 and a twelve month high of $11.73.
Hedge Funds Weigh In On Actuate Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in ACTU. OMERS ADMINISTRATION Corp bought a new stake in shares of Actuate Therapeutics in the 4th quarter worth $84,000. Mercer Global Advisors Inc. ADV bought a new position in Actuate Therapeutics in the 4th quarter worth approximately $130,000. Voss Capital LP purchased a new position in shares of Actuate Therapeutics in the fourth quarter valued at $440,000. Envestnet Asset Management Inc. bought a new stake in shares of Actuate Therapeutics during the 4th quarter valued at $83,000. Finally, BIOS Capital Management LP purchased a new stake in Actuate Therapeutics during the 4th quarter worth about $78,753,000.
About Actuate Therapeutics
(
Get Free Report)
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Actuate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.
While Actuate Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
